Table 2– Effect of inhibiting nitric oxide, superoxide and hydrogen peroxide bioavailability on hypoxic pulmonary vasoconstriction (HPV) in isolated perfused mouse lung

Experimental protocol	ΔP_pa mmHg (HPV response)
Experimental protocol	WT	Heterozygous	Hph-1
Maximum HPV	7.2±2.1	8.0±2.1	7.5±0.9
HPV + L-NAME (100 μM)	13.4±4.2^#	11.1±0.9^¶	12.8±0.7*
HPV + PTIO (10 μM)	9.8±0.7^#
HPV + catalase (200 U·mL⁻¹)	10.3±2.4	10.7±3.2^¶	11.7±3.1*
HPV + MnTMPyP (1 μM)	9.1±1.8	9.1±2.1	8.8±0.5

ΔP_pa: reduction in pulmonary arterial pressure; WT: wild type; L-NAME: N_ω-nitro-l-arginine methyl ester hydrochloride; PTIO: 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide; MnTMPyP: Mn(III) tetrakis(1-methyl-4-pyridyl) porphyrin pentachloride; ^#: p<0.05 compared with WT controls; ^¶: p<0.05 compared with heterozygous controls; *: p<0.05 compared with hph-1 controls.